Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders

Anne T Berg,Christopher H Thompson,Leah Schust Myers,Erica Anderson,Lindsey Evans,Ariela J E Kaiser,Katherine Paltell,Amanda N Nili,Jean-Marc DeKeyser,Tatiana V Abramova,Gerry Nesbitt,Shawn Egan,Carlos G Vanoye,Alfred L George
DOI: https://doi.org/10.1093/brain/awae125
IF: 14.5
2024-04-24
Brain
Abstract:SCN2A -related disorders secondary to altered function in the voltage-gated sodium channel Na V 1.2 are rare with clinically heterogeneous expressions that include epilepsy, autism, and multiple severe to profound impairments and other conditions. To advance understanding of the clinical phenotypes and their relation to channel function, 81 patients (36, 44% female, median age 5.4 years) with 69 unique SCN2A variants were systematically phenotyped and their Na V 1.2 channel function systematically assessed. Participants were recruited through the FamileSCN2A Foundation. Primary phenotype (epilepsy of neonatal-onset, N=27; infant onset, N=18; and later onset N=24; and autism without seizures, (N=12) was strongly correlated with a non-seizure severity index (p=0.002), which was based on presence of severe impairments in gross motor, fine motor, communication abilities, gastrostomy tube dependence, and diagnosis of cortical visual impairment and scoliosis. Non-seizure severity was greatest in the neonatal-onset group and least in the autism group (p=0.002). Children with the lowest severity indices were still severely impaired, as reflected by an average Vineland adaptive behavior composite score of 49.5 (>3 SD below the test's norm-referenced mean). Epileptic spasms were significantly more common in infant onset (67%) than in neonatal (22%) or later-onset (29%) epilepsy (p=0.007). Primary phenotype also strongly correlated with variant function (p<0.0001); gain of function and mixed function variants predominated in neonatal-onset epilepsy, shifting to moderate loss of function in infant-onset epilepsy, and severe and complete loss of function in later-onset epilepsy and autism groups. Exploratory cluster analysis identified five groups representing (1) primarily later-onset epilepsy with moderate loss of function variants and low severity indices, (2) mostly infant-onset epilepsy with moderate loss of function variants but higher severity indices, (3) late-onset and autism only with the lowest severity indices (mostly 0) and severe/complete loss of function variants. Two exclusively neonatal clusters were distinguished from each other largely on non-seizure severity scores and secondarily on variant function. The relation between primary phenotype and variant function emphasizes the role of developmental factors in the differential clinical expression of SCN2A variants based on their effects on Na V 1.2 channel function. The non-seizure severity of SCN2A disorders depends on a combination of the age at seizure onset (primary phenotype) and variant function. As precision therapies for SCN2A -related disorders advance toward clinical trials, knowledge of the relationship between variant function and clinical disease expression will be valuable for identifying appropriate patients for these trials and in selecting efficient clinical outcomes.
neurosciences,clinical neurology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore the disease phenotypes associated with SCN2A gene mutations and their relationship with sodium channel function variations. Specifically, researchers hope to understand, through systematic phenotypic analysis and functional assessment, how the clinical manifestations of epilepsy patients with different ages of onset (neonatal period, infancy and later - onset) and autism spectrum disorder (ASD) patients are associated with specific SCN2A gene variant types. In addition, the study also aims to explore the effects of these gene variants on the function of NaV1.2 sodium channels and analyze how this influence further affects the severity of non - epileptic symptoms in patients. ### Research Background The SCN2A gene encodes a subunit of the voltage - gated sodium channel NaV1.2, which plays a crucial role in neurons and is responsible for the rapid rising phase of the action potential. Variations in the SCN2A gene have been associated with a series of neurodevelopmental disorders, including neonatal or infantile epilepsy, autism spectrum disorder, and intellectual disability. However, how these variations lead to different clinical phenotypes and the relationship between the specific characteristics of these phenotypes and changes in sodium channel function are not fully understood. ### Research Objectives 1. **Systematic Phenotypic Analysis**: Recruit 81 patients carrying SCN2A gene variants and conduct detailed clinical phenotypic descriptions of them, including the age, type, and other accompanying symptoms of epileptic seizures. 2. **Functional Assessment**: Use the automated patch - clamp technique to conduct functional assessments of 69 unique SCN2A gene variants to determine the effects of these variants on the function of the NaV1.2 sodium channel. 3. **Phenotype - Function Relationship**: Analyze the relationship between the clinical phenotypes of patients and the functional impacts of the SCN2A gene variants they carry, especially explore how different types of variants (such as gain - of - function, loss - of - function, etc.) affect the clinical manifestations of patients. ### Main Findings - **Phenotypic Diversity**: The study found that epilepsy patients with neonatal - onset are more common in gain - of - function or mixed - type variants, while epilepsy patients with infancy and later - onset are more common in moderate or severe loss - of - function variants. - **Non - Epileptic Symptoms**: The severity of non - epileptic symptoms is related to the age of epileptic seizures and the type of gene variants. Patients with neonatal - onset usually have more severe non - epileptic symptoms. - **Treatment Response**: Patients with neonatal - onset have a better response to certain sodium channel blockers (such as phenytoin), while patients with infancy and later - onset have a poorer response. ### Conclusion This study emphasizes that the effects of SCN2A gene variants on the function of NaV1.2 sodium channels show significant differences in patients of different age groups, and these differences further affect the clinical phenotypes of patients. Understanding these relationships is of great significance for future precision treatment of SCN2A - related diseases, which helps to select appropriate patients to participate in clinical trials and optimize the evaluation criteria for clinical outcomes.